{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/crohns-disease/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"a5629107-6649-5a0c-a706-90ad8bf14aa7","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 0343c2a5-cbc0-45a0-9ccb-4276c613e75c --><h2>Changes</h2><!-- end field 0343c2a5-cbc0-45a0-9ccb-4276c613e75c -->","summary":null,"htmlStringContent":"<!-- begin item f17fec8b-5041-43ca-b3a1-a24f0f36b527 --><!-- begin field aaf17127-f782-4671-85cf-8e7c0b40037e --><p><strong>August 2020</strong> — minor update. Broken URL link updated and typographical error corrected.</p><p><strong>April 2020</strong> — minor update. New management scenario created to provide information regarding COVID-19.</p><p><strong>May 2019</strong> — minor update. Information from the updated National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Crohn's disease. Management in adults, children and young people</em> (full NICE guideline) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">National Clinical Guideline Centre, 2019</a>] and<em> Crohn's disease: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/crohns-disease/references/\">NICE, 2019</a>] have been added to the topic. No major changes to recommendations have been made.</p><p><strong>August to September 2017</strong> — reviewed. A literature search was conducted in July 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The topic has undergone significant restructuring. The recommendations on the diagnosis and management of confirmed Crohn's disease have been amended in line with current evidence. The sections on specialist investigations and management have been updated and expanded. The Prescribing information section has been deleted and links made to other relevant CKS topics.</p><!-- end field aaf17127-f782-4671-85cf-8e7c0b40037e --><!-- end item f17fec8b-5041-43ca-b3a1-a24f0f36b527 -->","topic":{"id":"a55bf0e9-c7ea-505e-b7ff-5093105336e5","topicId":"7057d96d-a527-4391-84a1-c39953de3eae","topicName":"Crohn's disease","slug":"crohns-disease","lastRevised":"Last revised in August 2020","chapters":[{"id":"9c1b7d20-f572-5a3c-845f-3f4b65f646e1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6b9f2bb0-4b7b-5373-ace6-15e38cc8904f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2a50fc53-dced-5bb1-83cf-20d5ce4f9e8e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a5629107-6649-5a0c-a706-90ad8bf14aa7","slug":"changes","fullItemName":"Changes"},{"id":"1a920dcd-3a15-527f-9fc2-97be951c56cc","slug":"update","fullItemName":"Update"}]},{"id":"79cdca68-ce3a-5435-bca1-8393c4d809a6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"123f065a-c1e6-59ef-a0f6-fa3212214c90","slug":"goals","fullItemName":"Goals"},{"id":"d3e5c61e-a5b9-586a-8698-69a0c0f79a5f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b41011e0-33e6-52d3-9434-5f29d0baeeb8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f3bcc082-58a6-51db-a805-173080268884","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a5948dc8-4eac-58f3-8d64-68a80aeb4059","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7082be71-4889-5e95-bd5f-27917f361203","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"65c06b36-b686-57f1-be7f-6fae62c4deb0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3fa00303-9d62-51cf-819b-dbad0041831e","slug":"definition","fullItemName":"Definition"},{"id":"6890604a-a1f2-5be2-94b0-d2471c85fdbc","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"0d0050de-d075-540a-9c7c-ed50c6ed1243","slug":"prevalence","fullItemName":"Prevalence"},{"id":"05aa7fe4-c9b9-51f0-bf41-2369861eba6c","slug":"complications","fullItemName":"Complications"},{"id":"67cb018a-e79e-5636-bd84-67fe57bf28c2","slug":"extra-intestinal-manifestations","fullItemName":"Extra-intestinal manifestations"},{"id":"d2c1974d-3136-58a1-b5ba-55826ab8a286","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"14a7e92b-d43e-5b64-b357-c1a4d063afb3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"32cf487b-92a9-5d33-949e-023023aede46","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"5440444f-1635-5240-bea3-54d84e6067f5","slug":"investigations","fullItemName":"Investigations"},{"id":"f7a2e718-21ad-5956-a862-8f8406ca2f8b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"a49169c9-856e-51c3-94cc-76e3f02f6073","fullItemName":"Management","slug":"management","subChapters":[{"id":"c4ee1de2-52a2-5289-82bd-c3377ae84b6c","slug":"suspected-crohns-disease","fullItemName":"Scenario: Suspected Crohn's disease"},{"id":"b3e71531-764c-58b2-aa02-ece1993fb53f","slug":"confirmed-crohns-disease","fullItemName":"Scenario: Confirmed Crohn's disease"},{"id":"b822e9cd-227b-54db-9bfd-57cf52a4e663","slug":"fertility-pregnancy-breastfeeding-with-crohns-disease","fullItemName":"Scenario: Fertility, pregnancy, and breastfeeding with Crohn's disease"},{"id":"9a2be3f2-65c0-5e62-9b89-9aef0f5df386","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"82ab51ab-f7f0-5464-a0dc-cb566bb3f629","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"771b1e3f-3c10-5c86-bbb4-5ff669ca2d44","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fb296c54-fd91-56fc-ab19-6fd4bb759030","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"efff8f5f-5a26-5e56-a428-b3155279fcef","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"420029a0-c51b-5ffc-a7f3-71940eccb5ba","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"09872916-a68f-57e9-b064-aab1b782ca32","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"dc3e796d-dda1-58f4-b43f-f4ce100ebfc2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a0922fda-b50c-5cff-8ccd-19fef4fe47f1","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2a50fc53-dced-5bb1-83cf-20d5ce4f9e8e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"c3d73223-a31a-5735-84d5-73978cd350b9","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 9901971f-f080-4a44-929a-e82874d87bbf --><h3>Previous changes</h3><!-- end field 9901971f-f080-4a44-929a-e82874d87bbf -->","summary":null,"htmlStringContent":"<!-- begin item cd1849b3-8b6a-4fa4-935b-f8f30ce273a7 --><!-- begin field ec96a5cc-c4c6-4f28-8864-27434749e50d --><p><strong>December 2016</strong> — minor update. The section on adverse effects of corticosteroids has been updated in line with the manufacturer's Summary of Product Characteristics (2016). Myocardial ischaemia or infarction and arrhythmia have been added as possible adverse effects of infliximab in line with the manufacturer's Summary of Product Characteristics (2016).</p><p><strong>November 2016 </strong>— minor update. Adverse effects of loperamide have been updated in line with the Food and Drug Administration (FDA) drug safety communication (2016), warning that exceeding the maximum dose can cause serious cardiac problems including QT interval prolongation, Torsades de pointes or other ventricular arrhythmias, syncope, and cardiac arrest.</p><p><strong>September 2016</strong> — minor update. The brand name Octasa<sup>®</sup> has been added to the Prescribing information section as another licensed and available preparation of mesalazine, in line with the British National Formulary (2016).</p><p><strong>April 2015</strong> — minor update. Text updated to reflect a new law on drugs and impaired driving, in line with the Department for Transport <em>Guidance for health professionals on drug driving</em> (July 2014).</p><p><strong>February 2013</strong> — minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>December 2012</strong> — reviewed. A literature search was conducted in November 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of this topic. No major changes to clinical recommendations have been made.</p><p><strong>August 2012</strong> — text in the Prescribing Information section has been updated to clarify recommendations for the use of oral hormonal contraception while taking metronidazole or ciprofloxacin.</p><p><strong>May 2011</strong> — minor update to the text to reflect guidance issued by the British Society of Gastroenterology. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>April 2011 </strong>— minor update. The National Institute for Health and Care Excellence (NICE) have issued guidance on colonoscopic surveillance of people with Crohn's disease. Issued in June 2011.</p><p><strong>February to June 2010 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field ec96a5cc-c4c6-4f28-8864-27434749e50d --><!-- end item cd1849b3-8b6a-4fa4-935b-f8f30ce273a7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}